Premium
Up‐regulation of a novel mRNA (NY‐CO‐1) involved in the methyl 4‐methoxy‐3‐(3‐methyl‐2‐butenoyl) benzoate (VT1)‐induced proliferation arrest of a non‐small‐cell lung carcinoma cell line (NSCLC‐N6)
Author(s) -
Carbonnelle D.,
Jacquot C.,
Lanco X.,
Le Dez G.,
Tomasoni C.,
Briand G.,
Tsotinis A.,
Calogeropoulou T.,
Roussakis C.
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.1197
Subject(s) - cell growth , cell cycle checkpoint , cancer research , cell cycle , in vitro , messenger rna , cell culture , biology , lung cancer , cell , medicine , gene , genetics
It is now well known that treatment of tumors, especially non‐small‐cell lung cancer (NSCLC), remains limited and it is urgent to develop strategies that target tumor cells and their genetic features. In this regard, our work is about genetic modifications arising in an in vitro NSCLC cell line after treatment with a chemical substance, methyl 4‐methoxy‐3‐(3‐methyl‐2‐butenoyl) benzoate (VT1). First, we showed that VT1 induces arrest of proliferation by blocking cells in the G1 phase of the cell cycle. Second, we use “differential display” strategy to clarify the genetic mechanisms involved in this proliferation arrest. A novel mRNA, NY‐CO‐1 (New‐York Colon 1), of unknown function showed up‐regulated expression after treatment. Application of “antisense” strategy confirmed this novel mRNA induction was effectively linked to growth arrest. Therefore, these data provide new information about mechanisms participating in arrest of proliferation of tumor cells and open new ways of treatment to target tumor growth. © 2001 Wiley‐Liss, Inc.